Mr. Dane Stevens reports

OPTIMI HEALTH ANNOUNCES EQUITY INCENTIVE GRANTS AND CORPORATE UPDATE

Optimi Health Corp. has arranged a series of equity compensation and marketing initiatives designed to support its growth strategy and enhance market awareness.

Equity incentive grants

Optimi announces that, pursuant to its equity incentive plan and subject to acceptance by the Canadian Securities Exchange, it has approved the grant of an aggregate of 850,000 stock options and 555,000 restricted share rights to certain directors, officers, employees and key individuals associated with the company.

The options are exercisable for a period of five years from the date of issuance, subject to applicable vesting provisions, at an exercise price of 50 cents per common share. The RSRs will vest and convert into common shares of the company for no additional consideration, subject to applicable vesting provisions. Any common shares issued pursuant to the options or RSRs will be subject to a statutory hold period expiring four months and one day following the date of issuance.

Marketing and sponsored research initiatives

The company further announces that it has entered into a research sponsorship agreement with Diamond Equity Research LLC (DER), an unregistered equity research firm headquartered in New York, United States. Under the terms of the agreement, DER will provide independent research coverage on the company, including the preparation of an initiation report outlining the investment opportunity and incorporating at least one financial valuation model.

Research coverage and related content are expected to be distributed through various financial and social media platforms, including FactSet, LinkedIn, Yahoo Finance, Google Finance, X (formerly Twitter), Zacks and Thomson One.

Marketing and investor awareness services

In addition, Optimi announces that it has engaged Native Ads Inc. to provide investor awareness and promotional services, subject to approval by the Canadian Securities Exchange. The digital media and content distribution campaign is expected to commence in the first quarter of 2026 and continue for a term of up to 24 months or until the approved budget is fully expended.

Under the agreement, Native Ads will conduct a digital advertising campaign intended to increase awareness and understanding of the company and its regulated pharmaceutical product portfolio, including its MDMA (3,4-methylenedioxymethamphetamine) and psilocybin drug products. The campaign will include advertising across search engines, financial publications and financial websites. The company has approved a budget of up to $350,000 (U.S.) for these services.

Native Ads will not receive any securities of the company as compensation, and the agreement does not include any performance-based compensation factors. Native Ads and Optimi are arm's-length parties, and neither Native Ads nor its principals hold any direct or indirect interest in the securities of the company as of the date of the agreement.

About Optimi Health Corp.

Optimi Health is a Canadian GMP-compliant (good manufacturing practices) pharmaceutical drug manufacturer licensed by Health Canada for the handling of controlled substances and GMP production. Operating from two 10,000-square-foot facilities in British Columbia under a drug establishment licence issued by Health Canada, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated markets, with products currently available for prescription use in Australia through the Authorized Prescriber Scheme and in Canada through the Special Access Program.

We seek Safe Harbor.